aspergillosis
ASPERGILLOSIS
Aspergillosis encompasses a variety of clinical syndromes depending on host immunity factors.
It is caused by Aspergillus, an ubiquitous, soil-dwelling, filamentous fungus that grows on soil, food, dead leaves, household dust, etc. It grows best at 37ºC and the small spores are easily inhaled and deposited deep in the lungs.
The most common pathogens are Aspergillus fumigatus, A. flavus, A. niger and A. terreus.
Aspergilloma is a conglomeration of intertwined Aspergillus hyphae, fibrin, mucus and cellular debris within a pulmonary cavity or an ectatic bronchus.

Aspergillosis Drug Information

Drug Information

Indication: Invasive aspergillosis; fluconazole-resistant serious invasive Candida infections (eg, C krusei); serious...

Indication: Invasive candidiasis in childn & adults. Oesophageal candidiasis in adults, adolescents ≥16 yr & el...

Indication: Invasive aspergillosis in patients w/ disease refractory to amphotericin B or intolerant to these drugs. Fusar...

Indication: Cap: Vulvovag & oral candidosis; dermatomycosis, plantar tinea pedis & palmar tinea manus, pityriasis ...

Indication: Rheumatic fever, RA, allergic diseases, nephritic syndrome, bronchial asthma & other corticosteroid-indica...

Indication: Vulvovag candidosis, pityriasis versicolor, dermatomycosis, oral candidosis, onychomycosis caused by dermatoph...

Indication: Allergic, collagen, dermatological, GI, desquamative gingivitis, hematologic, tuberculous meningitis, ophth, r...

Indication: Bronchial asthma, allergic disease, RA, juvenile RA, rheumatoid myocarditis, rheumatic myelitis, psoriasis, os...

Indication: Primary or secondary adrenocortical insufficiency; rheumatic & hematologic disorders; bronchial asthma; co...

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 02 Dec 2020

People with HIV (PWH) who are hospitalized due to COVID-19 may have an increased mortality risk, according to a study from the UK.

Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pearl Toh, 18 Sep 2020
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.